7月9日电，呼吸系统药物制造商维罗纳制药美股夜盘短线拉升超16%，报道称默沙东接近达成以100亿美元的价格将其收购。

Core Viewpoint - Verona Pharma, a manufacturer of respiratory drugs, experienced a short-term surge of over 16% in after-hours trading, following reports that Merck is close to finalizing a $10 billion acquisition deal [1] Company Summary - Verona Pharma's stock price increased significantly, indicating strong market interest and potential investor confidence in the company's future prospects [1] - The reported acquisition by Merck at a valuation of $10 billion highlights the strategic importance of Verona Pharma's product offerings in the respiratory drug market [1] Industry Summary - The respiratory drug manufacturing sector is witnessing consolidation, as evidenced by Merck's interest in acquiring Verona Pharma, which may lead to increased competition and innovation within the industry [1] - The potential acquisition reflects a broader trend of large pharmaceutical companies seeking to enhance their portfolios through strategic acquisitions in specialized therapeutic areas [1]